Other COVID-19 Interventional Studies with Macrolides:
As of May 3, 2020, the Cochrane COVID-19 Study Register lists 490 interventional studies of which 285 are randomized trials (25). In the https://www.ncbi.nlm.nih.gov/pubmed site there are 7947 published papers on Covid-19 (26) and at US ClinicalTrials.gov, which is a resource provided by the U.S. National Library of Medicine, only 3 clinical trials were found for macrolides, all for azithromycin and non for clarithromycin, but only one using azithromycin as single agent for Covid-19 (27). This is a short description of these trials: 1. Hydroxychloroquine vs. Azithromycin for Hospitalized Patients With Suspected or Confirmed COVID-19 (HAHPS). This is a Phase2 randomized Interventional  study in which 300 patients will be enroll. Patients in the Hydroxychloroquine arm will receive Hydroxychloroquine 400 mg by mouth twice daily for 1 day, then 200 mg by mouth twice daily for 4 days (dose reductions for weight < 45 kg or GFR (glomerular filtration rate)<50ml/min). Patients in the Azithromycin arm will receive Azithromycin 500 mg on day 1 plus 250 mg daily on days 2-5 (may be administered intravenously per clinician preference). If the patient has already received azithromycin prior to randomization, the prior doses will count toward the 5 day total. It is now recruiting. It was First Posted : April 1, 2020, and it is done by the University of Utah (ClinicalTrials.gov Identifier: NCT04329832) (28). 2. Azithromycin for  COVID-19.  Treatment in Outpatients Nationwide (ACTION). This individually randomized telemedicine-based trial organized by University of California, San Francisco will evaluate the efficacy of a single dose of 1 gr Azithromycin for prevention of progression of COVID-19 in patients with a recent positive SARS-CoV-2 test who are not currently hospitalized. Was First Posted on April 2, 2020 and is not still recruiting patients. They have an estimated enrollment of 2271 participants. They propose an individually-randomized, placebo-controlled trial to determine the efficacy of a single dose of 1gr Azithromycin for prevention of COVID-19 progression to hospitalization (ClinicalTrials.gov Identifier: NCT04332107)(29). 3. Azithromycin in Hospitalized COVID-19 Patients (AIC). The present study is a randomized, double-blind, controlled, clinical trial, with the approval of the ethics committee will be conducted on patients who have a positive test confirming COVID-19 in Shahid Modarres Medical Education Center and Hospital in Tehran. Patients will be randomly assigned to the two arms of the study and after completing the course of treatment and collecting and analyzing the necessary information from each patient, the results of the study will be published both on this site and in the form of an article in a reputable international journal. It is not yet recruiting and was First Posted on April 24, 2020. Shahid Modarres Hospital, Shahid Beheshti University of Medical Sciences and Health Services. Tehran, Iran, Islamic Republic of, ( ClinicalTrials.gov Identifier: NCT04359316 ) (30). No paper or study at this time was found either in any of these sites for Clarithromycin and COVID-19 (25) (26) (27).